Brief: Quanterix Announces FDA 510(K) Submission For A Multi-Analyte Algorithmic Blood Test For Alzheimer’S Disease Detection
03/02/2026 13:49
Feb 3 (Reuters) - Quanterix Corp QTRX.O: QUANTERIX ANNOUNCES FDA 510(K) SUBMISSION FOR A MULTI-ANALYTE ALGORITHMIC BLOOD TEST FOR ALZHEIMER’S DISEASE DETECTION Source text: ID:nBw7HxHp3a Further company coverage: QTRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quanterix
See all newsBrief: Alzpath And Quanterix Expand Strategic Licensing Agreement To Advance Next Generation Alzheimer's Disease Biomarker Research
Quanterix Corporation reports results for the quarter ended June 30 - Earnings Summary
Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Quanterix Corporation expected to post a loss of 46 cents a share - Earnings Preview
Quanterix Corp expected to post a loss of 46 cents a share - Earnings Preview